DOCSLIB.ORG

Roots Analysis Pvt. Ltd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Roots Analysis Pvt. Ltd Roots Analysis Pvt. Ltd. http://www.marketresearch.com/RootsAnalysisPvt.Ltd. -v3981/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm EST Fridays: 5:30am - 5:30pm EST Email: [email protected] MarketResearch.com 3.2. DRUGS INDICATED FOR ONCOLOGICAL DISEASES A large number of the pipeline drugs are indicated for oncological diseases. Companies such as Amgen, Merrimack and Genentech are developing these anti-cancer bispecific antibodies. It is common to see that a drug is simultaneously being tested for several indications. For example, catumaxomab, which has approval for malignant ascites, is being tested for its role in ovarian and gastric cancer in phase II clinical trials. Drugs such as blinatumomab and duligotumab are also a part of one drug - several applications list. Table 3.1 tabulates the oncological bispecific antibody drugs and provides information such as target antigen, indication and the phase of development. Table 3.1 Oncological Bispecific Antibodies in Clinical Trials S. No. Drug Target Antigen Collaborators Technology Indication Phase of Development INDUSTRY DRUGS 1. Blinatumomab / CD3 x CD19 Amgen BiTE ALL, DLBCL, 2, 2, 2 MT103 / MEDI- NHL 538 2. CD20Bi / FBT- CD3 x CD20 Fresenius Biotech, Triomab B Cell 1 / 2 A05/ Lymphomun Trion Pharma Malignancies SAMPLE PAGES Report Page 33 3. TF2 CEA x HSG Immunomedics Dock and Lock Pretargeting and 1 / 2 Imaging - Cancer 4. Catumaxomab EpCAM x CD3 Fresenius Triomab Malignant Ascites, Marketed, 2, 2 (Removab) Biotech GmbH, Gastric cancer, Trion Ovarian cancer 5. MM-111 HER2 x HER3 Merrimack HSA-body Gastric cancer; 2, 1, 1 Pharmaceuticals Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers; HER2 positive solid tumours 6. Duligotumab EGFR x HER3 Genentech Two-in-One Metastatic 2, 2 Dual Action colorectal cancer, Fab (DAF) Recurrent / metastatic SCCHN 7. Solitomab EpCAM x CD3 Amgen BiTE Solid Tumors 1 (AMG110, MT110) Continued on Page 34, 35, 36, 37, 38 Copyright © 2013 Roots Analysis Private Limited Page | 3 DULIGOTUMAB / MEHD7945A / RG7597 (ROCHE / GENENTECH) 4.4.1. OVERVIEW Duligotumab is a bispecific antibody drug in development by Roche. It is based on the Genentech’s two-in-one technology. The technology was developed by scientists working at the Antibody Engineering and Protein Engineering Department at Genentech. The basis of ‘two-in-one’ technology is the introduction of certain mutations in the Fv region, such that each Fv region in the antibody has affinity for two different antigens. However, at any given time each Fv region will bind to any one of the two recognised antigens; this is essentially because the two antigens are recognised by a similar set of antigen binding residues. The drug is currently being tested in phase II clinical trials for its role in treatment of recurrent / metastatic squamous cell carcinoma of the head and neck (SCCHN) and KRAS positive relapsed / refractory metastatic colorectal cancer (mCRC). The drug is also in phase I for the indication of metastatic epithetlial tissues. It first entered clinical development in 2010. 4.4.4. COMPETITION FOR DULIGOTUMAB Table 4.6 highlights the competitive drugs for duligotumab. Erbitux and Vectibix are antibody basedSAMPLE therapeutics approved for the treatment of KRAS PAGES wild type mCRC, the same indication as duligotumab. Erbitux is the closest competitor and the active comparatorReport in clinical Page trials 55 for duligotumab. Annual treatment cost for treatment of colorectal cancer with Erbitux is around USD 140,000 per patient. Duligotumab is likely to have an advantage over Erbitux with respect to the dosing schedule. Unlike Erbitux, which is administered through intravenous infusion every week, duligotumab is being tested for intravenous administration every two weeks. Table 4.6 Duligotumab / MEHD7945A / RG7597: Competitor Drug Analysis Drug Company Indication Type of Drug Route of Administration Erbitux BMS, Eli Lilly KRAS wild type Recombinant Intravenous infusion (Cetuximab) mCRC, SCCHN human/mouse chimeric mAb Vectibix Amgen KRAS wild type mAb Intravenous infusion (Panitumumab) mCRC Xeloda (Capecitabine) Genentech mCRC Small molecule Oral Stivarga (Regorafenib) Bayer mCRC Small molecule Oral Zaltrap Regeneron / Sanofi mCRC Recombinant fusion Intravenous infusion (ziv-aflibercept) protein Source: Roots Analysis Copyright © 2013 Roots Analysis Private Limited Page | 4 4.9.2.1. MM-111: CURRENT DEVELOPMENT STATUS The drug is in trials for several indications such as gastric cancer and breast cancer. MM-111 is in phase II trials as a combination therapy with paclitaxel, or paclitaxel and trastuzumab in patients with advanced gastric, esophageal and gastroesophageal junction cancers. The company started patient enrollment on this trial in July 2013 and expects to enroll 180 patients across centers in the US, Europe, Asia and Africa. The drug is also in phase I trial for treatment of refractory Her2 amplified, heregulin positive breast cancer. Merrimack Pharmaceuticals is also developing a companion diagnostic tool that will help identify patients likely to respond to treatment with MM-111 based on their expression levels of ErbB2 (HER2), ErbB3, heregulin and other factors that the trials will suggest. Table 4.14 describes the ongoing trials for the drug. 4.9.4. MM-111 SALES FORECAST: LONG TERM, 2018 - 2023 Figure 4.15 and Table 10.33 highlight the ‘base scenario’ sales forecast of MM 111. The sales forecasts are based on the expectation that the drug will receive market approval in 2018. SAMPLE PAGES Figure 4.15 MM-111 Market (USD MM), Long Term Forecast:Report 2018 Page - 2023 (Base74 Scenario) 79 52 32 20 12 8 2018E 2019E 2020E 2021E 2022E 2023E Source: Roots Analysis Under the ‘base scenario’, we forecast the drug to achieve sales of USD 8 million during its launch year. This is likely to grow rapidly to reach USD 79 million by 2023, representing a CAGR of 60%. The details of the conservative and the aggressive scenarios are listed in Tables 10.34 and 10.35 in the Appendices. Copyright © 2013 Roots Analysis Private Limited Page | 5 5.2. BISPECIFIC ANTIBODY PRODUCTION: TECHNOLOGY PROVIDERS AND AVAILABLE TECHNOLOGIES The bsAbs market is flooded with companies that provide various bispecific creation technology platforms. These offer technologies belonging to the first and the latest generations of bispecific antibodies. Table 5.2 tabulates these technology providers along with their bispecific antibody technology platforms. Table 5.2 Bispecific Antibody Technologies Platforms S. No. Company Technology First Generation 1. Trion Pharma Triomab Second Generation 2. AbbVie DVD-Ig 3. Ambrx Not declared 4. Adimab Adimab technology 5. Ablynx Nanobodies 6. Allozyne CAESAR Biociphering Electrostatistically Matched SAMPLEAmgen PAGES 7. F(ab)2 (Micromet) Report Page 90 BiTE 8. AstraZeneca (MedImmune) Tx2Ab 9. Baliopharm Chemical Crosslinking Beijing ABT Genetic Engineering 10. scBsAb Technology Co. 11. Biogen-Idec Hercules 12. Biotecnol Tribody Technology 13. Bicycle Therapeutics Bicycle technology 14. Covagen FynomAb 15. Dutalys DutaMab 16. Epigen Biotech COMBODY 17. EMD Serono Seed (Strand-Exchange Engineered Domain) Body 2 18. F-star (mAb ) Luz-Y (Use of Leucine Zippers) Two In One 19. Genentech Knob-into-Holes Bis-Fab/ DAF (Dual Action Fab) Continued on Page 91, 92 Copyright © 2013 Roots Analysis Private Limited Page | 6 5.3.3. BISPECIFIC T CELL ENGAGER / BiTE (AMGEN) BiTE technology was developed by Micromet based on research conducted at the University of Munich. A group of scientists from the University established Micromet in 1993, with headquarters in the US and a research facility in Germany. In March 2012, Amgen acquired Micromet for a payment of USD 1.16 billion. With this acquisition, Amgen gained the rights to BiTE technology platform and two pipeline molecules – MT103 in phase III and a yet unnamed molecule in phase I. 5.3.3.1. THE TECHNOLOGY BiTe based bispecific antibodies are formed by fusion of two scFv that have differing amino acid sequences or amino acid sequences from four different genes. Each BiTE bispecific antibody comprises of two scFv’s forming a single polypeptide of 55 kDa molecular size. Each BiTE antibody has a single N and C terminus. All BiTE antibodies recognise CD3 and another target antigen, which varies for each molecule. 5.3.3.2. DRUGS BASED ON BiTE Amgen, post acquisition of Micromet, has continued development of blinatumomab. Alongside, it also has developed other BiTE based bispecific antibodies. Furthermore, there are several more BiTESAMPLE antibodies in development by pharmaceutical companiesPAGES including Boehringer Ingelheim, Bayer, and MedImmune. Table 5.5 tabulates the drugs based on thisReport technology. PageThe BiTE 102 antibody farthest in clinical development is Blinatumomab, which is being developed in house by Amgen. The antibody is in phase II clinical trials for the treatment of NHL, ALL and DLBCL. Table 5.5 Drugs based on BiTE Technology Bispecific Target Cell Indicated Disease Phase of Collaborator / mAb Receptors Development Licensor Blinatumomab, CD19 X CD3 ALL, DLBCL, NHL 2, 2, 2 In-house MT103 Solitomab, AMG 110 EpCAM x CD3 Solid tumors 1 In-house MT111, MEDI 565 CEA x CD3 Gastrointestinal aden 1 MedImmune ocarcinomas (recruitment suspended) AMG 212, PSMA x CD3 Prostate cancer 1 Bayer BAY2010112 AMG 330 CD33 x CD3 AML Preclinical In-house Unnamed NA Multiple myeloma NA Boehringer Ingelheim Unnamed NA Solid tumour NA Bayer NHL - Non Hodgkins Lymphoma, ALL - Acute lymphoblastic Leukaemia DLBCL - Diffuse Large B-cell Lymphoma, AML - Acute Myeloid Leukaemia Source: Roots Analysis Copyright © 2013 Roots Analysis Private Limited Page | 7 .
Load more

Recommended publications
  • Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies
    Review Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? Joanie Del Bano 1,2,3,4,†, Patrick Chames 1,2,3,4, Daniel Baty 1,2,3,4 and Brigitte Kerfelec 1,2,3,4,*,† Received: 12 November 2015; Accepted: 18 December 2015; Published: 26 December 2015 Academic Editor: Christian Klein 1 Inserm, U1068, CRCM, Marseille F-13009, France; [email protected] (J.D.B.); [email protected] (P.C.); [email protected] (D.B.) 2 Aix-Marseille University, Marseille F-13284, France 3 CNRS, UMR7258, CRCM, Marseille F-13009, France 4 Institut Paoli-Calmettes, Marseille F-13009, France * Correspondence: [email protected]; Tel.: +33-491-828-833; Fax: +33-491-828-840 † These authors contributed equally to this work. Abstract: As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineering and the development of several technological platforms such as Triomab or bispecific T cell engagers (BiTEs), the “bispecifics” market has increased significantly over the past decade and may occupy a pivotal space in the future. Over 30 bispecific molecules are currently in different stages of clinical trials and more than 70 in preclinical phase. This review focuses on the clinical potential of bispecific antibodies as immune effector cell engagers in the onco-immunotherapy field. We summarize current strategies targeting various immune cells and their clinical interests.
    [Show full text]
  • Engineered Technologies and Bioanalysis of Multispecific Antibody Formats
    Journal of Applied Bioanalysis openaccess http://dx.doi.org/10.17145/jab.20.005 REVIEW Engineered Technologies and Bioanalysis of multispecific Antibody Formats Marta Amaral, Soraya Hölper, Christian Lange, Jennifer Jung, Hanno Sjuts, Sandra Weil, Melanie Fischer, Katarina Rado�evi�, Ercole Rao* Sanofi R&D, Biologics Research. *Correspondence: Sanofi-Aventis Deutschland GmbH, R&D, Biologics Research, Industriepark Höchst, H812, 65926 Frankfurt am Main, Germany. Phone: +49 6930515147. Email: [email protected] Citation: Amaral M, Hölper S, Lange C, Jung J, Sjuts H, Weil S, Fischer M, Rado�evic K, Rao E. Engineered Technologies and Bioanalysis of multispecific ABSTRACT antibody formats. J Appl Bioanal 6(1), The idea of designing multispecific antibodies capable of simultaneously 26-51 (2020). engaging two or more epitopes on the same or different antigens was developed more than 50 years ago. However, the molecular complexity of such Editor: molecules may pose significant challenges for their development and clinical Dr. Lin-zhi Chen, Boehringer use. Particularly challenging is to obtain the correctly assembled combination of Ingelheim Pharmaceuticals Inc., different polypeptide chains, which places significant demand on downstream Ridgefield, CT 06877, USA. process development, analytical characterization and control strategy. Here, we review the progress made in protein engineering to force the correct assembly of Received: July 29, 2019. different heavy and light chains, as well as upstream and downstream processes Revised: September 13, 2019. currently applied to control generation of unwanted byproduct species. We Accepted: September 16, 2019. cover in-depth the analytical methods available to characterize such complex molecules, focusing on mispairing analysis and functional characterization.
    [Show full text]
  • Ep 3178848 A1
    (19) TZZ¥__T (11) EP 3 178 848 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 14.06.2017 Bulletin 2017/24 C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) (21) Application number: 15198715.3 (22) Date of filing: 09.12.2015 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AL AT BE BG CH CY CZ DE DK EE ES FI FR GB yet been filed GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Cueni, Leah Noëmi et al Designated Extension States: F. Hoffmann-La Roche AG BA ME Patent Department Designated Validation States: Grenzacherstrasse 124 MA MD 4070 Basel (CH) (71) Applicant: F. Hoffmann-La Roche AG 4070 Basel (CH) (54) TYPE II ANTI-CD20 ANTIBODY FOR REDUCING FORMATION OF ANTI-DRUG ANTIBODIES (57) The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent comprising administration of a Type II anti-CD20 antibody, e.g. obinutuzumab, to the subject prior to administration of the therapeutic agent. EP 3 178 848 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 178 848 A1 Description Field of the Invention 5 [0001] The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent.
    [Show full text]
  • Overcoming Challenges for CD3-Bispecific Antibody Therapy In
    cancers Review Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors Jim Middelburg 1 , Kristel Kemper 2, Patrick Engelberts 2 , Aran F. Labrijn 2 , Janine Schuurman 2 and Thorbald van Hall 1,* 1 Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; [email protected] 2 Genmab, 3584 CT Utrecht, The Netherlands; [email protected] (K.K.); [email protected] (P.E.); [email protected] (A.F.L.); [email protected] (J.S.) * Correspondence: [email protected]; Tel.: +31-71-5266945 Simple Summary: CD3-bispecific antibody therapy is a form of immunotherapy that enables soldier cells of the immune system to recognize and kill tumor cells. This type of therapy is currently successfully used in the clinic to treat tumors in the blood and is under investigation for tumors in our organs. The treatment of these solid tumors faces more pronounced hurdles, which affect the safety and efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of this field and identify intrinsic hurdles for solid cancers. Furthermore, we describe potential solutions and combinatorial approaches to overcome these challenges in order to generate safer and more effective therapies. Abstract: Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities, sparse T-cell infiltration and impaired T-cell quality due to the presence of an Citation: Middelburg, J.; Kemper, K.; immunosuppressive tumor microenvironment, which affect the safety and limit efficacy of CD3- Engelberts, P.; Labrijn, A.F.; bispecific antibody therapy.
    [Show full text]
  • Tocilizumab, but Not Dexamethasone, Prevents CRS Without Affecting
    Open access Short report Tocilizumab, but not dexamethasone, J Immunother Cancer: first published as 10.1136/jitc-2020-000621 on 30 May 2020. Downloaded from prevents CRS without affecting antitumor activity of bispecific antibodies 1,2,3,4 1,2 1,2 3,4 Joseph Kauer , Sebastian Hörner, Lukas Osburg, Stefanie Müller, Melanie Märklin,3,4 Jonas S Heitmann,3,4 Latifa Zekri,1,2 Hans- Georg Rammensee,1,2,3 Helmut R Salih,3,4 Gundram Jung1,2 To cite: Kauer J, Hörner S, ABSTRACT However, a recent publication reports inhi- Osburg L, et al. Tocilizumab, but Bispecific antibodies (bsAb) and chimeric antigen receptor bition of bsAb-mediated T cell activation and not dexamethasone, prevents (CAR) T cells allow for antibody guided recruitment of T cells CRS without affecting antitumor tumor cell killing by dexamethasone during against tumors. Both are successfully used for treatment of 6 activity of bispecific antibodies. long- term stimulation. Moreover, steroid CD19 expressing leukemias, but may cause cytokine release Journal for ImmunoTherapy medication did not significantly increase the syndrome (CRS) as a major dose- limiting side effect. For of Cancer 2020;8:e000621. maximal tolerated dose of a CEAxCD3 bsAb in doi:10.1136/jitc-2020-000621 CRS prevention, steroids are recommended prior to bsAb 7 treatment, despite their well-kno wn lymphotoxic activity. a recent clinical study. The IL-6 receptor antibody tocilizumab is established for Meanwhile, the IL-6 receptor antibody tocili- ► Additional material is zumab is approved for treatment of severe published online only. To view treatment of CRS induced by CAR T cells, but was not please visit the journal online considered for CRS prevention in bsAb therapy.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • Bi-Specific and Tri-Specific Antibodies- the Next Big Thing in Solid Tumor Therapeutics Karie Runcie1, Daniel R
    Runcie et al. Molecular Medicine (2018) 24:50 Molecular Medicine https://doi.org/10.1186/s10020-018-0051-4 REVIEW Open Access Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics Karie Runcie1, Daniel R. Budman1,2, Veena John1,2 and Nagashree Seetharamu1,2* Abstract Antibody-based therapy has revitalized the world of cancer therapeutics since rituximab was first approved for the treatment of Non-Hodgkin’s Lymphoma. Monoclonal antibodies against cancer antigens have been successful strategies for only a handful of cancer types due to many reasons including lack of antibody specificity and complex nature of tumor milieu which interfere with antibody efficacy. Polyspecific antibodies are promising class of anti-cancer agents which can be directed at multiple tumor antigens to eradicate tumor cells more precisely and effectively. They may overcome some of these limitations and have already changed treatment landscape for some malignancies such as B cell acute lymphoblastic leukemia. Pre-clinical studies and early phase clinical trials have demonstrated that this approach may be an effective strategy even for solid tumors. This review focuses on the development of bispecific and trispecific antibody therapy for the treatment of solid tumor malignancies and highlights the potential they hold for future therapies to come. Keywords: Bispecific antibody, Trispecific antibody, Immunotherapy, Solid tumor Background efficacy in various cancers, these agents are rarely effect- Cancer remains the second leading cause of death in the ive as monotherapies and have several limitations. Acti- United States, with lung cancer being the leading cause vation of alternate molecular pathways, acquired of cancer deaths, followed by breast cancer in women changes in the tumor milieu, and suboptimal engage- and prostate cancer in men (Siegel 2017).
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors
    antibodies Review Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors Vladimir Voynov 1,*, Paul J. Adam 2, Andrew E. Nixon 1 and Justin M. Scheer 1 1 Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA; [email protected] (A.E.N.); [email protected] (J.M.S.) 2 Cancer Immunology & Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, 1121 Vienna, Austria; [email protected] * Correspondence: [email protected] Received: 13 September 2020; Accepted: 11 November 2020; Published: 18 November 2020 Abstract: T-cell Engaging bispecific antibodies (TcEs) that can re-direct cytotoxic T-cells to kill cancer cells have been validated in clinical studies. To date, the clinical success with these agents has mainly been seen in hematologic tumor indications. However, an increasing number of TcEs are currently being developed to exploit the potent mode-of-action to treat solid tumor indications, which is more challenging in terms of tumor-cell accessibility and the complexity of the tumor microenvironment (TME). Of particular interest is the potential of TcEs as an immunotherapeutic approach for the treatment of non-immunogenic (often referred to as cold) tumors that do not respond to checkpoint inhibitors such as programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) antibodies. This has led to considerable discovery efforts for, firstly, the identification of tumor selective targeting approaches that can safely re-direct cytotoxic T-cells to cancer cells, and, secondly, bispecific antibodies and their derivatives with drug-like properties that promote a potent cytolytic synapse between T-cells and tumor cells, and in the most advanced TcEs, have IgG-like pharmacokinetics for dosing convenience.
    [Show full text]
  • IMPROVE Patient Outcomes Thursday, Dec
    IMPROVE Patient Outcomes Thursday, Dec. 10, 2020 • Louisville, Ky. Live Virtual Program #LearnACI The 2020–2021 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association. SITC-0720-148 Thank You To Our Supporters The 2020–2021 Advances in Cancer ImmunotherapyTM series is generously supported in part by independent medical education grants from: DOUBLE-PLATINUM AstraZeneca Pharmaceuticals LP Merck & Co., Inc. PLATINUM Bristol Myers Squibb GOLD Amgen SILVER Exelixis, Inc. Table of Contents Letter from the President . 2 Program Details . 3 Program Planners and Faculty . 6 Program Schedule . 7 Disclosure Information . 8 Program Organizers . 11 Presentations Immunotherapy for the Treatment of Skin Cancers Jae Y. Jung, MD, PhD Norton Cancer Institute . 12 Immunotherapy for the Treatment of Lung Cancer Adam Lye, MD Norton Cancer Institute . 39 Immunotherapy for the Treatment of Hematologic Malignancies Joseph Maly, MD Norton Cancer Institute . 65 Immunotherapy for the Treatment of Genitourinary Malignancies Chandler H. Park, MD Norton Cancer Institute . 90 Immunotherapy for the Treatment of Head and Neck Cancers Aaron Spalding, MD, PhD Norton Cancer Institute . 106 Immunotherapy for the Treatment of Additional Solid Tumors: GI Mike Driscoll, MD Norton Cancer Institute . 121 Practical Barriers in Cancer Immunotherapy Treatment Lennea Coombs, MHS, PA-C Norton Cancer Institute . 136 Toxicity Management Laila Agrawal, MD Norton Cancer Institute . 154 What’s Next for Cancer Immunotherapy? Jaspreet S. Grewal, MD, PhD, MPH Norton Cancer Institute . 180 COVID-19 in Cancer Immunotherapy Joseph Flynn, MD, MPH Norton Cancer Institute .
    [Show full text]
  • Multifunctional Receptor-Targeting Antibodies for Cancer Therapy
    Review Multifunctional receptor-targeting antibodies for cancer therapy Yanni Zhu, Sung Hugh Choi, Khalid Shah During the past decade, monospecifi c antibodies targeting cell-surface receptors in diff erent tumour types have Lancet Oncol 2015; 16: e543–54 achieved substantial success and have been at the forefront of cancer treatment. However, redundant signalling and Molecular Neurotherapy and crosstalk between diff erent pathways within tumour cells and between tumour cells and their microenvironment can Imaging Laboratory, Stem Cell limit the effi cacy of receptor-targeted monospecifi c-based therapies. Advances in antibody engineering technologies Therapeutics and Imaging Program (Y Zhu PhD, have enabled strategies that simultaneously target multiple receptors to circumvent the limitations of conventional S H Choi PhD, K Shah PhD), monospecifi c therapies and achieve enhanced therapeutic effi cacy. In the past 5 years, a range of multifunctional, Department of Radiology receptor-targeting, antibody-based molecules have emerged, which allow targeting of multiple surface receptors on (Y Zhu, S H Choi, K Shah), and tumour cells and endothelial or immune cells in the tumour microenvironment. In this Review, we discuss the Department of Neurology (K Shah), Massachusetts rationales and strategies for the use of multifunctional receptor-targeting antibodies, their mechanisms of action, and General Hospital, Harvard the promises and challenges they hold as cancer therapeutics. This knowledge provides opportunities to improve Medical School, Boston, MA, current targeted therapy outcomes for patients with cancer. USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA (K Shah) Introduction penetrate to tumour tissues inaccessible to full-size Correspondence to: Antibody-based therapeutics have been one of the most antibodies.
    [Show full text]